^
    Back
    Association details:
    Biomarker:ITGB6 expression
    Cancer:Pancreatic Cancer
    Drug:sigvotatug vedotin (SGN-B6A) (Microtubule inhibitor, Integrin beta-6 -targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Cancer Ther
    Title:

    SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications

    Published date:
    08/25/2023
    Excerpt:
    The antibody component of SGN-B6A is specific for integrin beta-6 and does not bind other alpha-v family members. In preclinical studies, this ADC has demonstrated activity in vivo in models derived from non-small cell lung, pancreatic, pharyngeal, and bladder carcinomas spanning a range of antigen expression levels.
    DOI:
    10.1158/1535-7163.MCT-22-0817